Search clinical trials for: RPh201

Total 84 results

Regenera Pharma Ltd

Completed

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Non-arteritic Ischemic Optic Neuropathy | Optic Nerve Injuries

Israel
Hadassah Medical Organization

Withdrawn

The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements (CVS)

Chronic Vegetative State
Regenera Pharma Ltd

Withdrawn

Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn

Partial Thickness Burn | Second Degree Burn Less Than 5%TBSA

Israel
Regenera Pharma Ltd

Completed

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Mild to Moderate Dementia Due to Alzheimer's Disease | With or Without Coexisting Cerebrovascular Disease

Canada
Regenera Pharma Ltd
TransCom Global Ltd. (CRO)

Terminated

Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

Chronic Wound

Israel
Regenera Pharma Ltd
Syneos Health

Completed

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

Healthy Volunteers | Moderate to Severe Alzheimer Patients

Canada
Regenera Pharma Ltd

Terminated

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Nonarteritic Anterior Ischemic Optic Neuropathy

United States
Hadassah Medical Organization

Suspended

The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study (RPh-in-CVS)

Chronic Vegetative State

Israel
Canadian Cancer Trials Group
Innate Pharma

Completed

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Gynecologic Cancer

Canada
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

Healthy Subjects

United States
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Subjects With Varying Degrees of Renal Insufficiency and | Subjects With Normal Renal Function

United States
HK inno.N Corporation

Completed

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301

Parenteral Nutrition

Korea, Republic of
Novus Therapeutics, Inc

Completed

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Healthy Adult Volunteers

United States
Innate Pharma

Terminated

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Chronic Lymphocytic Leukemia

United States
Novus Therapeutics, Inc

Completed

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

Acute Otitis Media

United States
Innate Pharma

Terminated

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

Germany, Spain
Innate Pharma

Completed

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Acute Myeloid Leukemia

France
Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
Institut Paoli-Calmettes
Innate Pharma

Unknown

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (PIRAT)

Hematologic Malignancies

France
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Thyroid Eye Disease

United States
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Thyroid Eye Disease

United States
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
Helixmith Co., Ltd.

Completed

Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis

Osteoarthritis of the Knee
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

Bacterial Infections | Healthy Volunteers

Australia
Innate Pharma

Completed

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma (REMYKIR)

Multiple Myeloma

France
Public Health Vaccines LLC
Biomedical Advanced Research and Development Authority

Recruiting

Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects (PHV01)

Marburg Virus Disease

United States
argenx

Recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

Korea, Republic of, United States, Bulgaria, Belgium, Denmark, Georgia, Greece, Lithuania, Argentina
argenx

Active, not recruiting

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

Generalized Myasthenia Gravis

United States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
Innate Pharma

Completed

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (KIRMONO)

Smoldering Multiple Myeloma

United States
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
argenx

Completed

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Healthy Volunteers

Netherlands
argenx

Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

United States, Germany, Spain, Korea, Republic of, Austria, Turkey, Lithuania, Australia, Thailand, Serbia, Poland, Italy, France, Netherlands, Argentina, United Kingdom, Georgia, Belgium, Bulgaria, Canada, Cyprus, Denmark, Greece, Hu... and more
argenx

Completed

SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)

Healthy Volunteers

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
argenx

Completed

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

Generalized Myasthenia Gravis

Spain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
TRPHARM

Withdrawn

Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator

Healthy
argenx

Completed

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Bioequivalence

United States
argenx

Recruiting

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (ADAPT Jr +)

Generalized Myasthenia Gravis

United States, Netherlands, Belgium, Poland, United Kingdom
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Ipsen

Terminated

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (SSTR2+)

Small Cell Lung Cancer and Breast Cancer

United States, Austria, France, Switzerland, Germany, United Kingdom, Belgium

3

Subscribe